Jacobs Bruce N. sold $8.9M of KYMR
Jacobs Bruce N. (Chief Financial Officer) sold 77,109 shares of Kymera Therapeutics, Inc. (KYMR) at an average of $114.96 ($110.54–$117.70, $8.86M total) across 8 trades on 2026-06-30 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The CFO’s open-market sale totals ~$8.86M across multiple trades at prices ranging from ~$110.54 to ~$117.70, with holdings after the transaction of 244,883 shares; the sale is under a 10b5-1 plan.
Market read
Provides a fresh, primary-source datapoint on insider selling magnitude and execution details, but lacks any fundamental catalyst.
What to watch
Traders may over-weight insider sales; without accompanying guidance/clinical/regulatory updates, the filing is unlikely to change fundamental expectations.
Background
The article is an SEC Form 4 insider transaction disclosure for Kymera Therapeutics, Inc. (KYMR).
Ticker impact
Kymera Therapeutics CFO Bruce N. Jacobs sold about $8.86M of KYMR shares via an open-market transaction under a 10b5-1 plan on 2026-06-30.
Likely limited immediate price impact; any effect is more about sentiment/positioning than fundamentals.
The filing is primary-source (Form 4) and transaction size is meaningful, but the presence of a pre-arranged 10b5-1 plan typically dampens interpretability versus discretionary selling.
Market effects
No direct sector read-through; this is company-specific insider activity.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than a negative view on the business.
Key entities
- issuerKymera Therapeutics, Inc.
Subject of the Form 4 insider transaction; CFO Bruce N. Jacobs sold shares under a 10b5-1 plan.
- insiderBruce N. Jacobs
Chief Financial Officer; executed the open-market sale disclosed in the Form 4.
